Search PubMed⌕ Search

Biomedical subjects

E C Huskisson

Publications and source records attributed to E C Huskisson.

At least 91 records · Page 5Linked to original sources
PubMed1982

The drug treatment of osteoarthritis.

Recent recognition of the importance of inflammation and the efficacy of anti-inflammatory drugs in osteoarthritis has increased their importance in the routine management of the disease. Anti-inflammatory drugs do more than just relieving pain; they reduce the duration of morning stiffness, stiffness after sitting and the number of tender joints. Patients usually prefer them to simple analgesics. The choice of anti-inflammatory drugs is determined largely by individual variation in response so that it may be necessary to try a number of different compounds before finding one which suits a particular patient. Intra-articular steroids are disappointing in that though effective, their action is very brief. Intra-articular orgotein may have a useful role in the treatment of osteoarthritis. Simple analgesics are useful for patients with mild or intermittent pain when regular treatment is inappropriate. Specific therapy, like penicillamine for rheumatoid arthritis or allopurinol for gout, is urgently required. Better understanding of the pathogenesis of the disease may make this possible.

Adrenal Cortex Hormones↗
PubMed1981

Fluproquazone for osteoarthritis.

Fluproquazone (100 mg t.d.s.) was compared in a double-blind cross-over trial with indomethacin (25 mg t.d.s.) and placebo. Fluproquazone and indomethacin were both superior to placebo. The active drugs were comparable in most measures of efficacy though significantly more patients preferred indomethacin to fluproquazone. Side-effects were few and did not lead to withdrawal of treatment.

Adult↗
PubMed1981

How frequently should anti-inflammatory drugs be given? A study with indoprofen.

Indoprofen, despite its relatively short plasma half-life, was just as effective given twice daily as when the same daily total was given in four divided doses. There was a trend in favour of the twice daily regime for changes in morning pain and the duration of morning stiffness. Preferences were equally divided between the two regimes and efficacy was the usual reason for patients preferring one or other. Side-effects were no more frequent with the twice daily regime. Pharmacokinetics are no substitute for clinical experiment in planning the dosage regime of a non-steroidal anti-inflammatory drug.

Arthritis, Rheumatoid↗
PubMed1981

An articular index for the assessment of osteoarthritis.

An articular index was devised for the sequential assessment of patients with osteoarthritis (OA). Forty-eight joint units, chosen to reflect the characteristic pattern of the disease, were scored for tenderness on pressure or movement on a 4-point scale. Four observers examined patients to assess inter- and intraobserver error. The index was highly reproducible both within and between observers; intraobserver error was, however, significantly smaller. In a double-blind, cross-over trial the index was sufficiently sensitive to detect a statistically significant difference between the responses of patients with OA to an anti-inflammatory agent and to a simple analgesic. It is likely to be a useful addition to current methods of measurement in osteoarthritis.

Acetaminophen↗
PubMed1981

Sausage digit due to radish bacillus.

We wish to draw attention to a very characteristic but little known syndrome. An elderly woman presented with a 'sausage finger', rheumatological jargon used to describe diffuse swelling of the digit. This proved to be a proliferative tenosynovitis caused by an atypical mycobacterium, Mycobacterium terrae, or the radish bacillus.

Aged↗
PubMed1981

A single-dose analgesic study of naproxen sodium and soluble aspirin in patients with rheumatoid arthritis.

Nineteen patients with moderate or severe pain due to rheumatoid arthritis were entered into a double-blind, crossover comparison of single doses of 550 mg naproxen sodium and 900 mg soluble aspirin. Pain relief, measured on a visual analogue scale, showed a rapid onset of action of both drugs. Pain relief reached 50% of its maximum within 1 hour on both drugs. There were no significant differences in the pain relief/time curves. Five patients found no relief of pain with either drug but of the remaining 14 patients 10 reported an onset of action of both drugs within half an hour. Nine patient on naproxen sodium and 7 on soluble aspirin rated pain relief as good or very good. At the end of the study, 7 patients preferred soluble aspirin, 4 preferred naproxen sodium and the remainder gave no preference. There were no side-effects on eigher drug.

Arthritis, Rheumatoid↗
PubMed1981

Piroxicam: what's new?

Explore the source record for details and available documents.

Drug Administration Schedule↗
PubMed1981

Three trials of indoprofen.

Three trials have been used to document various properties of indoprofen. As a simple analgesic, indoprofen (200 mg) was superior to placebo and at least as effective as aspirin (700 mg). As an anti-inflammatory, indoprofen (200 mg four times daily) was superior to both ibuprofen (300 mg four times daily) and placebo. With regular administration, the effect of indoprofen reached a plateau within 24 hours of the start of treatment. Long term administration confirmed the safety of indoprofen and the overall incidence of side effects was similar to that associated with ibuprofen therapy. Equal numbers of patients were withdrawn from the indoprofen and ibuprofen groups but the reasons for withdrawal were different. Patients were withdrawn from the ibuprofen group because of lack of effect and from the indoprofen group because of gastric side effects.

Anti-Inflammatory Agents↗
PubMed1981

Orgotein in osteoarthritis of the knee joint.

A double-blind study showed that four weekly intra-articular injections of 4 mg orgotein were superior to four weekly injections of saline in reducing pain, the duration of morning stiffness and effusions in patients with osteoarthritis. Forty patients with active osteoarthritis of the knee joint were studied. Patients without demonstrable effusion in the joint to be injected were excluded from the study. They were assigned at random to two treatment groups. The treatments appeared identical and the trial was therefore double-blind. The groups were well matched for age, sex, duration of disease and most other measurements made at the start of the study. Orgotein was safe and well tolerated. It caused only slightly more adverse reactions than placebo. Patients receiving orgotein showed no greater radiological deterioration than those receiving placebo.

Anti-Inflammatory Agents↗
PubMed1980

5-Thiopyridoxine in rheumatoid arthritis: clinical and experimental studies.

Twelve patients with rheumatoid arthritis who had failed to respond to or developed side effects preventing further use of penicillamine were given 5-thiopyridoxine (5-TP). These patients were compared with 48 patients with similar indications randomly assigned to placebo or penicillamine. Both 5-TP and penicillamine were superior to placebo, and the effectiveness of the two active drugs was similar. Both produced a gradual amelioration of symptoms and signs of the disease accompanied by reduction in erythrocyte sedimentation rate, rheumatoid factor titer, and immunoglobulins. Nine patients on 5-TP were able to continue treatment with good control of the disease for at least 18 months. Toxic effects included rashes, proteinuria, loss of taste, and mouth ulcers. Patients who had developed a particular side effect with penicillamine did not necessarily do the same with 5-TP. This is the second mercaptan compound which has suppressive effects on the clinical and laboratory features of rheumatoid arthritis. Because of their similarities, 5-TP and penicillamine were studied in various experimental systems in an attempt to find some common biochemical or pharmacologic action. Among the properties studied were the effects on copper, vitamin B6 metabolism, dermal collagen, and mixed disulfide formation. Results with animal models of inflammation were also examined. The only common action was enhancement of the secondary lesions of adjuvant arthritis.

Animals↗
PubMed1980

Clinical experience with tolmetin sodium.

Two studies are reported with tolmetin sodium. The first compared tolmetin sodium, phenylbutazone and placebo in rheumatoid arthritis. The second compared tolmetin sodium and aloxiprin in osteoarthritis and soft tissue rheumatism. In the first study, a double-blind crossover trial involving 12 patients, tolmetin sodium (1600 mg daily) was shown to be superior to placebo and comparable to phenylbutazone (400 mg daily). The reductions in morning stiffness and pain were statistically significant when compared to placebo. Tolmetin sodium and aloxiprin were compared in the treatment of osteoarthritis in a single-blind study which investigated efficacy and safety over a 3-month period. Initial dosages were 1600 mg tolmetin sodium and 6 g aloxiprin (equivalent to 5 g aspirin) daily. Thirty-four patients were enrolled in the study. Both drugs produced an improvement over the 3-months treatment period. The reduction in pain was statistically significant. The dosage of tolmetin sodium remained at 1600 mg daily for the 3-month duration of the study but side-effects necessitated the reduction of the dosage of aloxiprin in many patients and after 3-months' treatment the mean dosage was 4 g daily. Five patients withdrew from the tolmetin sodium group and 11 from the aloxiprin group. Adverse reactions including limiting side-effects, were about twice as common with aloxiprin compared to tolmetin sodium.

Arthritis, Rheumatoid↗
PubMed1980

Treatment of rheumatoid arthritis with levamisole.

Levamisole has been shown to be an effective, penicillamine-like drug. Its action is slow, it improves extra-articular features of the disease and reduces ESR and rheumatoid factor titre. Comparison with penicillamine has shown the two drugs to be comparable in effectiveness. Experience with different dosage regimes of levamisole suggest that 150 mg weekly is the optimal dose. It is as effective as larger doses and with fewer adverse reactions. Problems with levamisole have included neutropenia and rashes. The latter are sometimes severe and vasculitic. As with penicillamine some of the late complications of levamisole appear to be associated with immune complex deposition.

Arthritis, Rheumatoid↗